Twist Bioscience Corp
$ 61.88
3.46%
20 Apr - close price
- Market Cap 3,667,053,000 USD
- Current Price $ 61.88
- High / Low $ 62.09 / 58.99
- Stock P/E N/A
- Book Value 7.44
- EPS -1.27
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.17 %
- 52 Week High 62.09
- 52 Week Low 23.30
About
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Analyst Target Price
$52.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-02 | 2025-11-17 | 2025-08-04 | 2025-05-05 | 2025-02-03 | 2024-11-18 | 2024-08-02 | 2024-05-02 | 2024-02-02 | 2023-11-17 | 2023-08-04 | 2023-05-05 |
| Reported EPS | -0.5 | -0.45 | -0.47 | -0.66 | -0.53 | -0.59 | -1.47 | -0.79 | -0.75 | -0.81 | -0.78 | -1.04 |
| Estimated EPS | -0.43 | -0.5 | -0.57 | -0.56 | -0.63 | -0.7 | -0.77 | -0.82 | -0.78 | -0.92 | -1.14 | -1.12 |
| Surprise | -0.07 | 0.05 | 0.1 | -0.1 | 0.1 | 0.11 | -0.7 | 0.03 | 0.03 | 0.11 | 0.36 | 0.08 |
| Surprise Percentage | -16.2791% | 10% | 17.5439% | -17.8571% | 15.873% | 15.7143% | -90.9091% | 3.6585% | 3.8462% | 11.9565% | 31.5789% | 7.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.54 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TWST
2026-04-20 05:56:13
Twist Bioscience Corp is a key player in synthetic biology, offering scalable DNA synthesis technology for sectors like drug discovery, agriculture, and precision medicine. The company leverages proprietary silicon-based platforms for high-volume, low-cost DNA production, leading to an asset-light model that could drive significant revenue growth. While the company's competitive edge and strategic initiatives position it for strong future performance, investors should monitor profitability timelines, customer concentration, and potential risks like pricing erosion and intellectual property challenges.
2026-04-17 16:39:10
A Form 144 filing indicates proposed sales of Twist Bioscience Corp (NASDAQ: TWST) common shares by an insider, Adam Laponis. The filing details multiple past sales transactions by Laponis and also lists upcoming scheduled issuances from restricted stock vesting and an ESPP purchase. These transactions offer insights into insider activity for TWST.
2026-04-17 11:39:16
Twist Bioscience Corp. (TWST) reached a new 52-week high of $59.90, a significant increase from its $23.50 low, despite remaining unprofitable with a negative return on equity. The small-cap Pharmaceuticals & Biotechnology company has a market capitalization of $2,760 million and a 15.22% performance increase over the past year, though this is below the S&P 500's growth. Its financial metrics, including a price-to-book ratio of 6.05 and a debt-to-equity ratio of -0.41, indicate ongoing challenges, and the company does not offer a dividend.
2026-04-16 22:13:57
Adam Laponis, the CFO of Twist Bioscience Corp (TWST), sold 3,000 shares of the company on April 14, 2026. This transaction adds to his previous sales over the past year, with no insider buys recorded for the company during that period. Currently, TWST is trading at $55 per share, indicating it is modestly overvalued according to GuruFocus's intrinsic value estimate of $43.22.
2026-04-16 20:08:57
Twist Bioscience's CFO, Adam Laponis, sold 3,000 shares of common stock at $55.00 per share through a pre-arranged Rule 10b5-1 trading plan. Following this open-market transaction, Laponis still directly holds 122,694 shares. This insider sale is categorized as having a high filing impact and negative sentiment.
2026-04-15 11:39:32
Guggenheim has reiterated its Buy rating and $55.00 price target for Twist Bioscience (NASDAQ:TWST) after Amazon launched its new Bio Discovery platform, which partners with Twist Bioscience. The stock is currently trading above the target at $57.41. While the Amazon partnership is new and not yet factored into Twist Bioscience's guidance, Guggenheim sees it as a benefit to the company despite some skepticism about the platform's ability to produce superior commercial drugs.
